Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.
Takashi Seto(National Hospital Organization Kyushu Cancer Center), Kōichi Goto(National Cancer Center Hospital East), Masato Shingoji(Chiba Cancer Center), Katsuya Tsuchihara(Chiba Cancer Center), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Kiyotaka Yoh(National Cancer Center Hospital East), Yutaka Fujiwara(Aichi Cancer Center), Takuma Yokoyama(Kyorin University Hospital), Masahiro Kodani(Tottori University), Shunichi Sugawara(Sendai Kousei Hospital), Shingo Matsumoto(National Cancer Center Hospital East), Terufumi Kato(Taipei Veterans General Hospital), Kadoaki Ohashi(Okayama University Hospital)
Cited by 7
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k